BrightSpring Health Services Inc Dossier - Source-backed chat

BrightSpring Health Services Inc

BTSGNASDAQ

SectorHealth Care

IndustryHealth Information Services

Beta (adjusted)1.57

Intrinsic Value $69.66median of 6 methods · middle span $29-$263based on filings through 30 Jun 2026

Market Price $57.26Price as of 1 Oct 2026

UndervaluedIntrinsic value is 22% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $11.3B

Enterprise Value $13B

Shares Outstanding 226M diluted

Moat Rating None

Next Earnings Date30 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BrightSpring's operating momentum is constructive: second-quarter 2026 revenue increased 23.0%, adjusted EBITDA increased 44.2%, Home Health Care average daily census increased 54%, leverage declined to 2.15x, and management raised full-year revenue and adjusted EBITDA guidance. The offset is that aggregate prescriptions dispensed were approximately flat year over year, the company remains exposed to reimbursement, drug-pricing, labor, referral, integration, regulatory, and indebtedness risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets17 analysts · as of 18 Aug 2026

Low · most bearish analyst$70.00

Mean target$78.94

High · most bullish analyst$90.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$70.0019%

Prescription volume contracts persistently, reimbursement or drug-pricing pressure limits profitability, and labor or integration challenges slow Provider Services growth. Results fall below the lower ends of 2026 guidance or leverage rises above the monitoring threshold.

Base CaseCentral scenario

$78.9458%

Matches the consensus mean

BrightSpring performs within its 2026 guidance ranges, with strong Home Health Care and specialty-pharmacy activity offsetting broadly stable aggregate prescription volume. Adjusted EBITDA growth remains faster than revenue growth and leverage remains controlled.

Bull CaseUpside scenario

$90.0023%

BrightSpring reaches or exceeds the upper ends of its 2026 revenue and adjusted EBITDA guidance as specialty and infusion activity, Home Health Care census growth, and acquired-branch contributions remain strong. Continued deleveraging and operating leverage would strengthen the equity case.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter 2026 net revenue increased 23.0% year over year to $3.873 billion.
Second-quarter adjusted EBITDA increased 44.2% year over year to $206 million, materially faster than revenue.
Home Health Care average daily census increased 54% year over year to 46,448.
Management increased full-year 2026 guidance to revenue of $15.100-$15.425 billion and adjusted EBITDA of $820-$845 million.
Reported leverage declined to 2.15x from 2.27x in the preceding quarter following a $300 million first-lien-facility paydown.

Key Investment Risks

Quarterly prescriptions dispensed declined slightly year over year despite strong Pharmacy Solutions revenue growth, increasing dependence on mix and revenue per script.
Medicare, Medicaid, managed-care, PBM, drug-pricing, and third-party-payor changes could adversely affect reimbursement and profitability.
The company depends on recruiting and retaining nurses, pharmacists, therapists, caregivers, and other qualified personnel.
Acquisition integration, referral-source retention, regulatory compliance, cybersecurity, and substantial indebtedness remain material execution risks.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.